Abstract
Purpose The purpose of this study was to explore the risk factors for hemorrhagic transformation after endovascular treatment for acute large-vessel occlusion stroke and the risk factors for poor prognosis after endovascular treatment.
Methods A total of 132 cases of patients with acute large vessel occlusion stroke who underwent endovascular treatment in the Ningbo Medical Center Lihuili Hospital 1, 2021 to December 31, 2022 were included. According to whether there was intracranial hemorrhage within 72 hours after surgery, the patients were divided into hemorrhage transformation(HT) group and non-hemorrhage(no HT) group. The two groups were compared in terms of gender, age, history of hypertension, history of atrial fibrillation, and other factors to determine whether there were statistical differences.
Results Among the 132 included patients, 30 cases had hemorrhage transformation and 102 cases were in the non-hemorrhage group. Multivariate logistic regression analysis showed that the ASPECTS score on admission and the NLR within 24 hours after surgery were independent risk factors for hemorrhage transformation. The rate of good prognosis (MRS score 0-2) at discharge was 31.2%, and multivariate logistic regression analysis showed that advanced age, history of hypertension, and NIHSS score were independent risk factors for poor prognosis.
Conclusion The NLR within 24 hours after endovascular treatment is an independent risk factor for hemorrhage transformation in acute large vessel occlusion stroke and can be used as one of the predictive indicators. Advanced age, history of hypertension, and NIHSS score are independent risk factors for poor prognosis after endovascular treatment for acute large vessel occlusion stroke.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Ningbo medical and health brand discipline(NO:2022-F04).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of Ningbo Medical Center Li Huili Hospital
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The content of the article has been revised
Data Availability
All data produced in the present study are available upon reasonable request to the authors
